Familial risk of myeloid malignancies

Print Friendly, PDF & Email


Three generations of
women in a family
A large study has revealed “the strongest evidence yet” supporting genetic susceptibility to myeloid malignancies, according to a researcher. The study showed that first-degree relatives of patients with myeloid malignancies had double the risk of developing a myeloid malignancy themselves, when compared to the general population. The researchers... [Read Article]
Print Friendly, PDF & Email

JAK inhibition linked to B-cell lymphoma

Print Friendly, PDF & Email


Micrograph showing myelofibrosis
New research indicates that JAK inhibitors may increase the risk of lymphoma in patients with myelofibrosis (MF). The patients studied had a 15- to 25-fold higher risk of developing B-cell lymphoma if they received treatment with JAK inhibitors. The researchers speculate that screening MF patients for a pre-existing B-cell clone before starting... [Read Article]
Print Friendly, PDF & Email

Ropeg outperforms HU in PV patients of all ages

Print Friendly, PDF & Email


The 23rd Congress of the
European Hematology Association
Follow-up data suggest that ropeginterferon alfa-2b (ropeg) provides an advantage over hydroxyurea (HU) for patients with polycythemia vera (PV), regardless of their age. Two-year results from an extension study have shown that, compared to HU, ropeg produces higher rates of complete hematologic response (CHR) and molecular response... [Read Article]
Print Friendly, PDF & Email

Umbralisib can revitalize ruxolitinib in MF

Print Friendly, PDF & Email


Poster session at the 23rd Congress of the European Hematology Association
The PI3K delta inhibitor umbralisib can “augment or resurrect” responses to ruxolitinib in patients with myelofibrosis (MF), according to a speaker at the 23rd Congress of the European Hematology Association (EHA). Results of a phase 1 study showed that adding umbralisib to treatment with... [Read Article]
Print Friendly, PDF & Email

PU-H71 receives orphan drug designation for myelofibrosis

Print Friendly, PDF & Email


Micrograph showing myelofibrosis
The US Food and Drug Administration (FDA) has granted orphan drug designation to PU-H71 to treat patients with myelofibrosis. The drug specifically targets the epichaperome, a network of high-molecular- weight complexes found in multiple diseases, including cancer and neurologic disorders. These complexes enhance cellular survival, irrespective of tissue of origin or... [Read Article]
Print Friendly, PDF & Email

How ruxolitinib reduces thrombosis in MPNs

Print Friendly, PDF & Email


Polycythemia vera
Image courtesy of AFIP
Preclinical research helps explain how the JAK1/2 inhibitor ruxolitinib can reduce thrombosis in patients with myeloproliferative neoplasms (MPNs). Experiments revealed a link between JAK2V617F and the formation of neutrophil extracellular traps (NETs), which have been implicated in thrombosis. Researchers found that ruxolitinib reduced NET formation and decreased... [Read Article]
Print Friendly, PDF & Email

FDA approves test to diagnose MPNs

Print Friendly, PDF & Email


Essential thrombocythemia
The US Food and Drug Administration (FDA) has cleared use of QIAGEN’s ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) for the diagnosis of all myeloproliferative neoplasms (MPNs). The ipsogen JAK2 assay is a qualitative, in vitro diagnostic test designed to detect the JAK2 V617F/G1849T allele in genomic DNA extracted from... [Read Article]
Print Friendly, PDF & Email

Allo-HSCT leads to long-term survival in MF

Print Friendly, PDF & Email


Attendees at ASH 2017
Photo courtesy of ASH
© Todd Buchanan 2017
One of the largest single-center studies of fludarabine/melphalan-based allogeneic hematopoietic stem cell transplant (allo-HSCT) for patients with myelofibrosis (MF) shows excellent overall survival (OS) with a low risk of relapse, according to investigators. Allo-HSCT is the only potential curative treatment modality... [Read Article]
Print Friendly, PDF & Email